Delta 9 Cannabis Inc
TSX:DN
Delta 9 Cannabis Inc
TSX:DN
Price:
0.01
CAD
Market Cap:
CA$3.5m
Relative Value
There is not enough data to reliably calculate the relative value of DN.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
DN
Relative Value
Base Case
Not Available
Multiples Across Competitors
DN Competitors Multiples
Delta 9 Cannabis Inc Competitors
Delta 9 Cannabis Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| CA |
|
Delta 9 Cannabis Inc
TSX:DN
|
3.5m CAD | 0 | -0.2 | -36.3 | -2.9 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
987B USD | 15.1 | 47.8 | 32.2 | 34.2 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
592.7B USD | 6.3 | 22.1 | 15.4 | 18.9 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
295.7B CHF | 4.8 | 31.4 | 13.2 | 15.4 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
237.1B GBP | 5.4 | 31.3 | 17.3 | 24.4 | |
| CH |
|
Novartis AG
SIX:NOVN
|
248.2B CHF | 5.7 | 22.9 | 14.1 | 18.2 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
309B USD | 4.7 | 16.9 | 10.5 | 12.3 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD | 94 | -74.6 | 344.9 | 865 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 3.4 | 10.4 | 7.7 | 9 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
154.4B USD | 2.5 | 19.9 | 7.4 | 9.9 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
124.1B USD | 2.6 | 17.6 | 7.4 | 9.1 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
